Healing People with Better Biologics Faster
Triplebar addresses unmet medical needs by discovering better antibodies and biologics
Function First Antibody discovery
Triplebar’s Hyper-Throughput™ Screening system (HyTS) brings function forward using The Triplebar™ Platform. With HyTS™, we are able to screen through millions of candidates from both biological and synthetic libraries to find the right antibody with the best profile on an accelerated discovery timeline. This leads to better pharmaceutical solutions with early commercial access.
Function-first screening matters
Traditional Binding-First Approach
- Biased to strong binders
- Excludes low-affinity binders that elicit function
- Includes binders to wrong epitope
- Searches for “harder” traits when the population is smallest
Triplebar's function first approach
- Screen directly for functional Abs
- Include low-affinity binders that elicit function
- Searches for “harder” traits when library is large
- Potential for target-agnostic discovery
Our Pipeline
Accelerate With Us
With our function first discovery platform, we deliver an asset ready for development, scale up, and manufacturing.